Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises ALAFCO in connection with leasing of 4 brand new Airbus A320-NEO to SAS, delivered by Airbus from a production facility in Hamburg
Mandate

Vinge advises ALAFCO in connection with leasing of 4 brand new Airbus A320-NEO to SAS, delivered by Airbus from a production facility in Hamburg

February 03, 2021

Vinge has advised ALAFCO Aviation Lease and Finance Company, a Kuwait based, world leading operator in the airplane leasing business, in connection with the lease of 4 Airbus A320-NEOs, the new, more fuel-efficient narrow-body airplane, to Scandinavian Airlines System Denmark-Norway-Sweden (SAS).

Vinge has also managed the registration of all these new airplanes at the Swedish Transport Authority in the Aircraft Register and collaborated with international law firms as regards registration security rights in the International Aircraft Register which is maintained in Dublin according to the Cape Town Convention.

Vinge’s team consisted of partner, Fredrik Wilkens, together with Henrik Schön, Project Manager, as well as Anton Sjökvist and Elias Bohlin.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025